IP Library Granted Patent US 8,614,325
Granted Patent B2
US 8,614,325 · App. 13/237,303 · Granted Dec 24, 2013

Modulators of cystic fibrosis transmembrane conductance regulator

Inventors: Xiaoqing Yang (San Diego, CA); Sara Sabina Hadida Ruah (La Jolla, CA); Peter Diederik Jan Grootenhuis (San Diego, CA); Fredrick F. Van Goor (San Diego, CA); Martyn Curtis Botfield (Concord, MA); Gregor Zlokarnik (La Jolla, CA)
Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,614,325
App. No.
13/237,303
Granted
Dec 24, 2013
Kind
B2
Abstract

This invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH 2 OH.

Claims (22)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH 2 OH.

2. A compound according to claim 1 , wherein R is CH 2 OH.

3. A compound according to claim 1 , wherein R is COOH.

4. A pharmaceutical composition comprising:

a compound of Formula I, according to claim 1 ; and

a pharmaceutically acceptable carrier or adjuvant.

5. The pharmaceutical composition according to claim 4 , wherein the compound of Formula I is a compound of the structure:

6. The pharmaceutical composition according to claim 4 , wherein the compound of Formula I is a compound of the structure:

7. The pharmaceutical composition of claim 4 , further comprising an additional agent selected from a mucolytic agent, a bronchodilator, an antibiotic, an anti-invective agent, an anti-inflammatory agent, a CFTR modulator, or a nutritional agent.

8. A kit for use in measuring the activity of CFTR or a fragment thereof in a biological sample in vitro or in vivo, comprising:

i. a composition comprising a compound of Formula I, according to claim 1 ; and

ii. instructions for:

a. contacting the composition with the biological sample; and

b. measuring the activity of said CFTR or a fragment thereof.

9. The kit of claim 8 , further comprising instructions for:

i. contacting an additional compound with the biological sample;

ii. measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound; and

iii. comparing the activity of the CFTR or a fragment thereof in the presence of the additional compound with the activity of the CFTR or a fragment thereof in the presence of a composition of Formula I.

10. The kit according to claim 9 , wherein the step of comparing the activity of said CFTR or a fragment thereof provides a measure of the density of said CFTR or a fragment thereof.

11. The kit according to claim 8 , wherein the compound of Formula I has the structure:

12. The kit according to claim 8 , wherein the compound of Formula I has the structure:

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 12, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037810/0283 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2011
From: YANG, XIAOQING; HADIDA RUAH, SARA S.; VAN GOOR, FREDRICK F.; BOTFIELD, MARTYN C.; ZLOKARNIK, GREGOR; GROOTENHUIS, PETER D.J.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 027193/0150 →
Continuity (3)
Continuation PCTUS2010028062 · Mar 19, 2010
Provisional Application 61162130 · Mar 20, 2009
Related Publication 20120071504A1 · Mar 22, 2012